Syntekabio Showcases AI-Driven Drug Discovery Solutions at BioTechX USA 2024
TL;DR
Syntekabio is the Title Sponsor and will give a keynote address at BioTechX USA, positioning itself as a leader in AI-driven drug development.
Syntekabio's AI-driven technologies enable pharmaceutical and biotech companies to test the validity of target proteins without upfront costs, followed by STB LaunchPad program for delivering validated results.
Syntekabio's AI-driven solutions improve and accelerate R&D activities, offering potential hits and optimized leads in drug discovery, antibody prediction, and cancer neoantigen discovery to develop novel and effective therapeutics.
Syntekabio's participation at BioTechX USA includes a keynote presentation on addressing data scarcity in drug discovery with AI models, and a session on flexible molecular docking for neoantigen and antibody drug prediction.
Found this article helpful?
Share it with your network and spread the knowledge!
Syntekabio (KOSDAQ: 226330), an artificial intelligence (AI) based drug development company, has announced its participation as the Title Sponsor at BioTechX USA, scheduled for September 17-18, 2024, in Philadelphia, PA. The company will deliver a keynote address, present in-depth talks on its AI-driven solutions, and host a booth to engage with potential clients and industry leaders.
Dr. Jongsun Jung, CEO of Syntekabio, expressed enthusiasm about the event, noting the significance of the company's 'Develop Now, Pay Later' offer. This initiative allows clients to validate a target protein of interest without incurring any upfront costs. Syntekabio aims to demonstrate the potential of its AI technologies in improving and accelerating research and development (R&D) activities. The company boasts strong capabilities in identifying potential hits, optimizing small molecule leads, and excelling in antibody and cancer neoantigen discovery.
Attendees of BioTechX USA can schedule a meeting with Syntekabio or visit their booth (#401) to learn how their AI-driven solutions can address current pipeline challenges. Key presentations include a keynote by Dr. Jonathan Witztum, CTO of Syntekabio USA, on addressing data scarcity in drug discovery with physics-based AI models, and a session by Dr. Jung on flexible molecular docking for neoantigen and antibody drug prediction.
The 'Develop Now, Pay Later' model stands out as a pivotal offering from Syntekabio. This model enables pharmaceutical and biotechnology companies to test the validity of target proteins without initial financial commitment. Once a project's viability is proven, Syntekabio employs its STB LaunchPad program, powered by the DeepMatcher® technology platform, to deliver optimized leads and IND-enabled candidates. Clients are only billed once validated results are achieved, adding a layer of financial flexibility and trust in the drug discovery process.
In addition to this model, Syntekabio will spotlight its in silico biologics platforms, Neo-ARSTM and Ab-ARSTM, which facilitate personalized or universal neoantigen cancer vaccine and novel antibody drug prediction. These cutting-edge solutions are designed to tackle complex challenges in drug discovery, equipping researchers with powerful tools to develop novel and effective therapeutics.
Syntekabio's AI capabilities extend across a vast database of over 10 billion known compounds and 1,400 drug targets compatible with in vitro and in vivo studies, covering more than 70% of human diseases. The company's AI Bio-Supercom Center, with its extensive infrastructure of 5,000 servers, 40,000 CPU cores, and 2,500 GPUs, fuels these advanced algorithms. This robust technological foundation supports Syntekabio's mission to accelerate the drug discovery and development process.
Curated from News Direct
